Etelcalcetide Hydrochloride News

← Back to News Overview

---

Etelcalcetide Hydrochloride currently has 0 news articles, with 20 predicted indications.

This page combines the AI-predicted indications for Etelcalcetide Hydrochloride with the latest health news. Indications highlighted in orange have recent news coverage.

Drug Information

• Original indication: Parsabiv is indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on haemodialysis therapy.
• Evidence level: L5
• Predicted indications (20):
  • hyperphosphatemia (disease) (99.4%)
  • esophageal varices with bleeding (99.3%)
  • esophageal varices without bleeding (99.3%)
  • varicose disease (99.1%)
  • glaucoma (98.9%)
  • pancreatitis (98.8%)
  • primary hyperoxaluria (98.7%)
  • primary immunodeficiency syndrome due to p14 deficiency (98.6%)
  • severe congenital neutropenia (97.9%)
  • Barth syndrome (97.8%)
  • familial apolipoprotein C-II deficiency (97.6%)
  • autosomal recessive severe congenital neutropenia due to JAGN1 deficiency (97.5%)
  • cyclic hematopoiesis (97.4%)
  • Steel syndrome (97.4%)
  • familial hyperphosphatemic tumoral calcinosis/hyperphosphatemic hyperostosis syndrome (97.4%)
  • tumoral calcinosis, hyperphosphatemic, familial (97.3%)
  • autosomal recessive severe congenital neutropenia due to G6PC3 deficiency (97.1%)
  • autosomal recessive severe congenital neutropenia due to CSF3R deficiency (97.0%)
  • autosomal recessive severe congenital neutropenia due to CXCR2 deficiency (96.9%)
  • X-linked severe congenital neutropenia (96.8%)

View full drug report →

Related News (0)

No related news yet. When news mentions this drug, it will be collected and shown here automatically.

Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.